Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) has shared an update.
CSL Limited has announced its full-year financial results for the year ending June 30, 2025. The results presentation, led by the CEO and CFO, will be webcast live, providing stakeholders with insights into the company’s financial performance and strategic direction. This announcement is significant as it reflects CSL’s ongoing commitment to transparency and its strategic positioning within the biotechnology industry.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$325.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company based in Melbourne, Australia. The company specializes in the development and delivery of innovative medicines that save lives and help people with serious medical conditions. CSL’s primary products include plasma-derived therapies, vaccines, and recombinant proteins, with a strong market focus on immunology, hematology, and critical care.
YTD Price Performance: -3.21%
Average Trading Volume: 743,260
Technical Sentiment Signal: Buy
Current Market Cap: A$130.9B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.